Ultragenyx Pharmaceutical Inc 's Cash & cash equivalent grew by 20 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Ultragenyx Pharmaceutical Inc 's Quick Ratio to 0.39, Quick Ratio remained below Ultragenyx Pharmaceutical Inc average.

Within Major Pharmaceutical Preparations industry 400 other companies have achieved higher Quick Ratio than Ultragenyx Pharmaceutical Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1239 to 2933.

Explain Quick Ratio?
How much Cash & cash equivalents RARE�s has?
What are RARE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RARE/financial-strength

https://api.csimarket.com/api/v1/companies/RARE/fundamentals

https://api.csimarket.com/api/v1/companies/RARE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RARE Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	48.28 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-64.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.39	Subscribe	Subscribe	Subscribe	Subscribe
RARE's Total Ranking	# 2933	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	10.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	20 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 401
Healthcare Sector	# 764
Overall Market	# 2933

Quick Ratio Statistics
High	Average	Low
24.28	7.11	0.36
(Mar 31 2014)		(Jun 30 2026)

Financial Statements
Ultragenyx Pharmaceutical Inc 's Current Liabilities	$ 389 Millions	Visit RARE's Balance sheet
Ultragenyx Pharmaceutical Inc 's Cash & cash equivalent	$ 150 Millions	Visit RARE's Balance sheet
Source of RARE's Sales		Visit RARE's Sales by Geography

Cumulative Ultragenyx Pharmaceutical Inc 's Quick Ratio

RARE's Quick Ratio for the trailling 12 Months

RARE Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	31.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-32.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.06	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1604	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	10.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-16.75 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RARE Financial Strength Comparisons >> Go to Compare RARE Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2026 to $389.00 millions, cumulative Quick Ratio decreased to 1.06 below the Ultragenyx Pharmaceutical Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Ultragenyx Pharmaceutical Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2908 to 4016.

Explain Quick Ratio?
How much Cash & cash equivalents RARE�s has?
What are RARE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 901
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.86	2.03	0.4
(Mar 31 2015)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Phathom Pharmaceuticals Inc	1.06	$ 184.558 Millions	$ 174.902 Millions
Eton Pharmaceuticals Inc	1.03	$ 55.628 Millions	$ 54.095 Millions
Oragenics Inc	1.02	$ 2.227 Millions	$ 2.189 Millions
Geovax Labs Inc	1.01	$ 2.151 Millions	$ 2.135 Millions
Akebia Therapeutics Inc	0.98	$ 159.254 Millions	$ 162.349 Millions
Acadia Pharmaceuticals Inc	0.97	$ 322.365 Millions	$ 332.217 Millions
Alkermes Plc	0.97	$ 631.314 Millions	$ 651.933 Millions
Imunon Inc	0.95	$ 4.039 Millions	$ 4.239 Millions
Geron Corporation	0.94	$ 69.794 Millions	$ 74.248 Millions
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions
Jazz Pharmaceuticals Plc	0.80	$ 2,036.400 Millions	$ 2,540.300 Millions
Zomedica Corp	0.80	$ 7.281 Millions	$ 9.096 Millions
Pfizer Inc	0.79	$ 25,140.000 Millions	$ 31,726.000 Millions
Xencor Inc	0.78	$ 59.622 Millions	$ 76.266 Millions
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions
Ligand Pharmaceuticals Incorporated	0.75	$ 374.303 Millions	$ 500.569 Millions
Alumis inc	0.73	$ 57.691 Millions	$ 79.405 Millions
Rockwell Medical inc	0.71	$ 10.750 Millions	$ 15.073 Millions
Ionis Pharmaceuticals Inc	0.68	$ 296.303 Millions	$ 435.292 Millions
Liquidia Corporation	0.68	$ 396.091 Millions	$ 585.397 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Harrow Inc	0.66	$ 75.336 Millions	$ 114.224 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions

Date modified: 2026-11-06T12:59:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.